U.S. stocks closed higher, recovering from the prior day's selloff, as investors eyed higher Treasury yields and looked for signs of economic growth.» Read More
Spending on prescription drugs in the U.S. rose 13.1% in 2014, the biggest increase in more than a decade, according a report from Express Scripts.
PayPal looks to expand its bricks-and-mortar presence as it eyes a $280-million acquisition for Paydiant.
Sales growth from Hispanic consumers significantly outpaced that of Non-Hispanic shoppers across every beauty segment.
LOS ANGELES, Feb 19- As U.S. drugmakers face growing resistance to the high price of cutting-edge treatments, a handful of companies are working on a new payment model that rewards them for the long-term performance of their medicines. They include BioMarin Pharmaceutical Inc in San Rafael, California, and Sangamo BioSciences Inc in Richmond, California.
Feb 18- Samsung Electronics Co Ltd has bought U.S. mobile wallet startup LoopPay, signalling its intention to launch a smartphone payments service to compete with a recent offering from rival Apple Inc.. Apple, Google, and eBay Inc's PayPal have all launched services to allow users to pay in stores via smartphones. He would not be drawn on speculation the company...
Feb 17- CVS Health on Monday warned that costs of a potent new class of cholesterol treatments and other specialty drugs in development could eclipse those of expensive new medicines and overwhelm the healthcare system "if rigid cost control mechanisms are not put in place." CVS' call for cost controls follows sharp criticism from insurers, other payers and...
Feb 17- CVS Health Corp, the second-largest U.S. pharmacy chain operator, has warned that a new class of drugs being developed to lower "bad" cholesterol could cost the U.S. healthcare system as much as $150 billion per year. The new class of cholesterol drugs called PCSK9 inhibitors could be priced in the range of $7,000- $12,000 per year, CVS said.
David Dorman, CVS Health non-executive chairman, discusses the upside of CVS's healthy sales record and the outlook on health care costs.
Feb 11- Drugstore operator Rite Aid Corp agreed to buy pharmacy benefit manager EnvisionRx for about $2 billion, looking to cut drug procurement costs as reimbursement rates fall. Rite Aid's deal comes nearly a decade after larger rival CVS Health Corp bought Caremark Rx for $21 billion, the only other example of a drug chain buying a benefits manager.
Feb 11- Drugstore operator Rite Aid Corp said it would buy pharmacy benefit manager EnvisionRx for about $2 billion, entering the business of administering health plan benefits. The deal will help Rite Aid compete better with CVS Health Corp, which bought Caremark Rx for $21 billion in 2006.. The acquisition of EnvisionRx will also give Rite Aid access to more...
Billions of consumers belong to rewards programs. These are the most worthwhile.
Recommendations from the OECD may form the basis of a deal sought by Greece with euro zone finance ministers.
Discussing Q4 earnings, Stephen Holmes, Wyndham Worldwide CEO, says the company is not terribly impacted by a strong dollar.
Meredith Adler, food and drug analyst at Barclays Capital, discusses the significance of CVS's beat on the top line. Adler still likes the stock.
Feb 10- CVS Health Corp reported a better-than-expected quarterly net revenue, boosted by growth in its Medicaid business and strength in specialty drug sales. CVS became the first national drugstore chain in the United States to take cigarettes off its shelves from Oct. 1. CVS Health has focused on developing its specialty pharmacy business, which sells drugs...
Feb 10- CVS Health Corp, the No. 2 U.S. drugstore operator, reported a better-than-expected quarterly net revenue, helped by a jump in pharmacy same-store sales and strength in its specialty pharmacy business. CVS Health has focused on developing its specialty pharmacy business, which sells drugs to treat complex diseases such as multiple sclerosis, rheumatoid...
Some of the names on the move ahead of the open.
Investors are looking at further confirmation of an improving U.S. job market with two data points that come out on Tuesday.
A Vermont gas station attendant and janitor, invested in recognizable names when he amassed an $8 million fortune, his attorney said.
Jim Cramer sees that the market is in a sweet spot for earnings. With a new landscape, he's betting that these are the hot stocks to watch.